SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud by KaloBios Pharmaceuticals, Inc. and Certain Officers and Directors

NEW YORK--()--Levi & Korsinsky, LLP announces that it has commenced an investigation of KaloBios Pharmaceuticals, Inc. (“KaloBios” or the “Company”) (NASDAQGM:KBIO) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On December 17, 2015, news outlets reported that Martin Shkreli, the CEO of KaloBios, was arrested on securities fraud charges relating to his illegal use of stock from Retrophin Inc. to pay off debts associated with other unrelated business ventures. On this news, KaloBios shares plummeted pre-market, and trading has since been halted. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/kalobios-pharmaceuticals-kbio

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com

Release Summary

Levi & Korsinsky, LLP announces that it has commenced an investigation of KaloBios Pharmaceuticals, Inc.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com